The treatment of primary focal segmental glomerulosclerosis.
Nephrotic patients with primary focal segmental glomerulosclerosis (FSGS) have a poor prognosis with 50% progressing to end stage renal disease (ESRD) over 3 to 8 years. The achievement of a remission in proteinuria has been associated with a significantly improved renal survival as compared to those patients not attaining a remission. Unfortunately, spontaneous remissions are rare in FSGS, and the response to therapy has historically been poor. Recent experience with more aggressive immunosuppressive therapy has lead to an increase in the remission rate for FSGS patients and given rise to optimism in the treatment of this glomerulopathy.
Korbet
S M
SM
Department of Medicine, Rush Presbyterian St. Lukes Medical Center, Chicago, Illinois 60612, USA.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018450:Disease Progression; D005923:Glomerulosclerosis, Focal Segmental / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012008:Recurrence
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D011241:Prednisone